Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Ministers To Debate Pharma ‘Market Failures And High Prices’

Closer Member State Cooperation Is On The Agenda

Executive Summary

Varying levels of access to medicines across the EU are the result of market failures, high prices and pharmaceutical companies’ marketing strategies, says the Council of the EU, which will discuss these issues at the next meeting of European health ministers.

You may also be interested in...



EU Ministers Want Decisive Action On Medicines Access & Shortages

Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.

EU Needs More Teamwork On Drug Pricing & Access

EU member states are being urged by the European Commission to cooperate more closely on pricing and reimbursement, managed access deals and policies to promote generics and biosimilars.

France Backs Disclosure Of Public R&D Funding In Drug Price Negotiations

Civil society groups have welcomed a French parliamentary amendment that would require pharma firms to disclose any public R&D funding when negotiating drug prices with the health authorities. The pharmaceutical industry says the amendment does not take account of the realities of today's business model.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS141289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel